

PRESS RELEASE

Lelystad, 26 February 2010

Appeal against rejection of Oralgen Pollen registration dismissed

The administrative court of Zwolle-Lelystad issued a ruling today, 26 February 2010, regarding the appeal of Artu Biologicals Europe B.V. (Artu), a subsidiary of Fornix BioSciences N.V., against the rejection of the application to register the medicine Oralgen Pollen by the Dutch Medicines Evaluation Board (*College ter Beoordeling van Geneesmiddelen*, or CBG).

Artu submitted an application to register Oralgen Pollen to the CBG in 1992. The CBG refused to enter Oralgen Pollen in the register of proprietary pharmaceuticals, as on the basis of the data provided it was not convinced of the efficacy of the product. In February 2007, the CBG dismissed Artu's objection to the refusal, whereupon Artu filed an appeal with the court.

Artu provided the results of various clinical studies of the efficacy of Oralgen Pollen to the CBG, and requested the CBG to reconsider its decision. The CBG upheld its decision, since on the basis of these further studies it was still not convinced of the efficacy of the product. Artu also appealed against these decisions by the CBG.

The court took the view that in 2007 the CBG was entitled to its opinion that Artu had not sufficiently demonstrated the efficacy of Oralgen Pollen, and that the CBG was not obliged to revise its decision on the basis of the further studies.

Artu is studying the ruling and is taking advice regarding an appeal to the Administrative Jurisdiction Department of the Council of State. For the time being, the product Oralgen Pollen continues to be eligible for reimbursement on the basis of a previous ruling by the Court of The Hague.

END OF PRESS RELEASE

For more information, please contact:

Fornix BioSciences N.V.

Mr C.L. Bergman, CEO

Tel. (0320) 26 77 99

Website: www.fornix.nl

Profile of Fornix BioSciences N.V.

Fornix BioSciences N.V. is a listed company (Euronext Amsterdam, code AFORBI) which engages in the development and sale of diagnostic and therapeutic allergen products and the distribution of medical aids and medical and nursing consumables.

Fornix BioSciences N.V. has sites in Lelystad, Beuningen and Hamburg. The company currently has a workforce of around 130 and is active mainly in the Netherlands and Germany.

Its activities are carried out by two divisions, which in turn are made up of operating companies.

The Allergy Division, which consists of Artu Biologicals Europe and, since 1 June 2007, Artu Biologicals Deutschland, is the most profitable division. Its activities include the development, production and sale of a wide range of patient-friendly immunotherapeutic products, under the Oralgen®, Igevac® and other trade names. These products are used in the causal treatment of allergies triggered by various allergens, such as grass and tree pollen and house-dust mites. The development programme is supported by high-quality R&D activities and pan-European clinical studies of the effectiveness of the various products.

The Medical Aids Division, which consists of Laprolan in Beuningen, engages in the sale, marketing and distribution of a wide range of medical aids and medical and nursing consumables.